Mitigation of pandemic influenza: review of cost–effectiveness studies

References

• Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine(21), 1762–1768 (2003).
   Google Scholar
• Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am. J. Epidemiol.159(7), 623–633 (2004).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Nizam A, Xu S et al. Containing pandemic influenza at the source. Science309, 1083–1087 (2005).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DAT, Cauchemez S et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature437, 209–214 (2005).
   PubMed Web of Science ®Google Scholar
• Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA103, 5935–5940 (2006).
   PubMed Web of Science ®Google Scholar
• Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med.4, e15 (2007).
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost–effectiveness analyses of vaccination programmes. A focused review of modeling approaches. Pharmacoeconomics26, 191–215 (2008).
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost–effectiveness of vaccination programmes: a dynamic perspective. Stat. Med.18, 3263–3282 (1999).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med. Decis. Making23, 76–82 (2003).
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med. Decis. Making26, 434–446 (2006).
   PubMed Web of Science ®Google Scholar
• Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, UK (1991).
   Google Scholar
• Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton University Press, Princeton and Oxford; NJ, USA and UK (2008).
   Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ.15, 1295–1310 (2006).
   PubMed Web of Science ®Google Scholar
• Balicer RD, Huerta M, Davidovitch N, Grotto I. Cost–benefit of stockpiling drugs for influenza pandemic. Emerg. Infect. Dis.11(8), 1280–1282 (2005).
   PubMedGoogle Scholar
• Doyle A, Bonmarin I, Levy-Bruhl D, Le Strat Y, Desenclos J-C. Influenza pandemic preparedness in France: modeling the impact of interventions. J. Epidemiol. Community Health60, 399–404 (2006).
   Google Scholar
• Epstein JM, Goedecke DM, Yu F, Morris RJ, Wagener DK, Bobashev GV. Controlling pandemic flu: the value of international air travel restrictions. Plos One5, e401 (2007).
   Google Scholar
• Hak E, Meijboom MJ, Buskens E. Modelling the health-economic impact of the next influenza pandemic in The Netherlands. Vaccine24,6756–6760 (2006).
   Google Scholar
• Lee VJ, Phua KH, Chen MI et al. Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerg. Infect. Dis.12(1), 95–102 (2006).
   PubMed Web of Science ®Google Scholar
• Lugnér AK, Mylius SD, Wallinga J. The impact of model choice on cost–effectiveness studies for infectious diseases: the case of pandemic influenza. Health Econ. DOI: 10.1002/hec.1485 (2009) (Epub ahead of print).
   Google Scholar
• Lugnér AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost–effectiveness of stockpiling antiviral drugs. Eur. J. Public Health19(5), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Medema JK, Zoellner YF, Ryan J, Palache AM. Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply. Virus Res.103, 9–15 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis.5(5), 659–671 (1999).
   PubMed Web of Science ®Google Scholar
• Sadique MDZ, Adams EJ, Edmunds WJ. Estimating the costs of school closure for mitigating an influenza pandemic. BMC Public Health8, 135 (2008).
   PubMed Web of Science ®Google Scholar
• Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health12(2), 226–233 (2009).
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Edmunds WJ. Cost–effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg. Infect. Dis.14(2), 267–273 (2008).
   PubMed Web of Science ®Google Scholar
• Beutels P, Edmunds WJ, Smith RD. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Econ.17, 1317–1322 (2008).
   PubMedGoogle Scholar
• Daems R, Del Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine23, 5732–5742 (2005).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature442, 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• Nap RE, Andriessen MP, Meessen NE, van der Werf TS. Pandemic influenza and hospital resources. Emerg. Infect. Dis.13, 1714–1719 (2007).
   PubMed Web of Science ®Google Scholar
• Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic vaccine depends on age, risk and timing. Vaccine26, 3742–3749 (2008).
   PubMed Web of Science ®Google Scholar
• van Genugten MLL, Heijnen M-LA, Jager JC. Pandemic influenza and healthcare demand in The Netherlands: scenario analysis. Emerg. Infect. Dis.9, 531–538 (2003).
   PubMed Web of Science ®Google Scholar
• Dhankhar P, Dasbach EJ, Elbasha EH. Economics of stockpiling for an influenza pandemic. Lancet Infect. Dis.9, 459–460 (2009).
   Google Scholar
• ECDC working group on influenza A(H1N1)v. Preliminary analysis of influenza A(H1N1)v individual and aggregated case reports from EU and EFTA countries. Euro. Surveill.14, 2–6 (2009).
   Google Scholar
• Beutels P, Edmunds WJ, Antonanzas F et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics20, 1–7 (2002).
   PubMed Web of Science ®Google Scholar
• Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine25, 5945–5957 (2007).
   PubMed Web of Science ®Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ.10, 751–774 (2001).
   PubMed Web of Science ®Google Scholar
• Anonychuk AM, Tricco AC, Bauch CT et al. Cost–effectiveness analyses of hepatitis A vaccine. A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics26, 17–32 (2008).
   PubMed Web of Science ®Google Scholar
• Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost–effectiveness analyses of human papillomavirus vaccination. Lancet Infect. Dis.7, 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• Lynd LD, Goeree R, O’Brien BJ. Antiviral agents for influenza. A comparison of cost–effectiveness data. Pharmacoeconomics23, 1083–1106 (2005).
   PubMed Web of Science ®Google Scholar